Literature DB >> 31029588

Combining opioids and non-opioids for pain management: Current status.

Jun-Xu Li1.   

Abstract

Pain remains a global health challenge. For decades, clinicians have been primarily relying on μ-opioid receptor (MOR) agonists and nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management. MOR agonists remain the most efficacious analgesics available; however, adverse effects related to MOR agonists use are severe which often lead to forced drug discontinuation and inadequate pain relief. The recent opioid overdose epidemic urges the development of safer analgesics. Combination therapy is a well-established clinical pharmacotherapeutic strategy for the treatment of various clinical disorders. The combination of MOR agonists with non-MOR agonists may increase the analgesic potency of MOR agonists, reduce the development of tolerance and dependence, reduce the diversion and abuse, overdose, and reduce other clinically significant side effects associated with prolonged opioid use such as constipation. Overall, the combination therapy approach could substantially improve the therapeutic profile of MOR agonists. This review summarizes some recent developments in this field. This article is part of the Special Issue entitled 'New Vistas in Opioid Pharmacology'.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Abuse liability; Antagonists; Combination therapy; Opioids; Pain; Tolerance

Year:  2019        PMID: 31029588     DOI: 10.1016/j.neuropharm.2019.04.025

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Confronting the opioid crisis with basic research in neuropharmacology.

Authors:  Michael H Baumann; Gavril W Pasternak; Sidney S Negus
Journal:  Neuropharmacology       Date:  2020-01-17       Impact factor: 5.250

2.  Enhancement of Opioid Antinociception by Nicotine.

Authors:  Fernando Barreto de Moura; Sarah Louise Withey; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2019-09-16       Impact factor: 4.030

3.  Enhancement of Opioid Antinociception by Nicotinic Ligands.

Authors:  Fernando B de Moura; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2021-01-13       Impact factor: 4.030

4.  Ulinastatin Exhibits Antinociception in Rat Models of Acute Somatic and Visceral Pain Through Inhibiting the Local and Central Inflammation.

Authors:  Mei-Xiang Zhan; Li Tang; Yun-Fei Lu; Huang-Hui Wu; Yi-Qing Zou; Zhi-Bin Guo; Zhong-Mou Shi; Chen-Long Yang; Fei Yang; Guo-Zhong Chen
Journal:  J Pain Res       Date:  2021-05-04       Impact factor: 3.133

5.  The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats.

Authors:  C Austin Zamarripa; Tilak R Patel; B Cole Williams; Tanya Pareek; Hayley M Schrock; Thomas E Prisinzano; Kevin B Freeman
Journal:  Behav Pharmacol       Date:  2020-12       Impact factor: 2.277

6.  Electroacupuncture Inhibits the Activity of Astrocytes in Spinal Cord in Rats with Visceral Hypersensitivity by Inhibiting P2Y1 Receptor-Mediated MAPK/ERK Signaling Pathway.

Authors:  Jingming Zhao; Hui Li; Chong Shi; Tiezheng Yang; Baoshi Xu
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-25       Impact factor: 2.629

7.  Antinociceptive compounds and LC-DAD-ESIMSn profile from Dictyoloma vandellianum leaves.

Authors:  Lucas Silva Abreu; Iura Muniz Alves; Renan Fernandes do Espírito Santo; Yuri Mangueira do Nascimento; César Augusto Gonçalves Dantas; Gisele Graça Leite Dos Santos; Mireille Le Hyaric; Maria Lenise Silva Guedes; Marcelo Sobral da Silva; Cristiane Flora Villarreal; Eudes da Silva Velozo; Josean Fechine Tavares
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

8.  Pain-Administrable Neuron Electrode with Wireless Energy Transmission: Architecture Design and Prototyping.

Authors:  Chin-Yu Lin; Li-Chi Chang; Jyh-Chern Chen; Meng-Sheng Chen; Hsun Yu; Mei-Chih Wang
Journal:  Micromachines (Basel)       Date:  2021-03-25       Impact factor: 2.891

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.